| scholarly article | Q13442814 |
| P50 | author | Edward A. Stadtmauer | Q85544110 |
| David L. Porter | Q110797660 | ||
| P2093 | author name string | S Choi | |
| R H Vonderheide | |||
| D F Heitjan | |||
| S J Schuster | |||
| R Reshef | |||
| K S Tan | |||
| A Bagg | |||
| D E Tsai | |||
| M R Luskin | |||
| D S Heil | |||
| P2860 | cites work | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 |
| Report of the Committee on Hodgkin's Disease Staging Classification | Q28250452 | ||
| Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients | Q33634455 | ||
| Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. | Q33642308 | ||
| Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. | Q33710720 | ||
| Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease | Q34207259 | ||
| Identifying the patient at risk for post-transplant lymphoproliferative disorder | Q34275902 | ||
| Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial | Q34623991 | ||
| Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★). | Q34815054 | ||
| Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins | Q35068768 | ||
| Post‐transplant lymphoproliferative disorders: a morphologic, phenotypic and genotypic spectrum of disease | Q35228295 | ||
| Persistence of the Epstein-Barr virus and the origins of associated lymphomas | Q35715171 | ||
| Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs) | Q35849039 | ||
| Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation | Q35849338 | ||
| Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines. | Q37735259 | ||
| Lymphoma: risk and response after solid organ transplant. | Q37817421 | ||
| T-cell therapy in the treatment of post-transplant lymphoproliferative disease | Q38026758 | ||
| Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. | Q39464615 | ||
| The Seville expert workshop for progress in posttransplant lymphoproliferative disorders | Q39550390 | ||
| Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus | Q41670234 | ||
| Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. | Q42628866 | ||
| Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease | Q43936463 | ||
| The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients | Q43945318 | ||
| Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant | Q44116989 | ||
| Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients | Q44695050 | ||
| Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors. | Q44891160 | ||
| Treatment of PTLD with rituximab or chemotherapy | Q45167835 | ||
| A pilot trial of quantitative Epstein-Barr virus polymerase chain reaction in patients undergoing treatment for their malignancy: potential use of Epstein-Barr virus polymerase chain reaction in multiple cancer types | Q45344942 | ||
| Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction | Q45383857 | ||
| Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression | Q45406910 | ||
| Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells | Q45730808 | ||
| Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients | Q45738452 | ||
| Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? | Q45743876 | ||
| Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. | Q45754081 | ||
| Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? | Q45755509 | ||
| Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. | Q46006774 | ||
| Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. | Q46722604 | ||
| Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study | Q46778140 | ||
| Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression | Q46825318 | ||
| Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). | Q52935805 | ||
| Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. | Q53329306 | ||
| EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. | Q54543998 | ||
| Treatment of EBV-Related Post-Renal Transplant Lymphoproliferative Disease with a Tailored Regimen Including EBV-Specific T Cells | Q57275304 | ||
| Lymphomas occurring late after solid-organ transplantation | Q57703280 | ||
| Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation | Q58033185 | ||
| Gene Expression Profiling Reveals Clear Differences Between EBV-Positive and EBV-Negative Posttransplant Lymphoproliferative Disorders | Q58063835 | ||
| A Wilcoxon-type test for trend | Q70097327 | ||
| Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients | Q72659857 | ||
| Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction | Q74575937 | ||
| Lymphomas after solid organ transplantation: a collaborative transplant study report | Q76376056 | ||
| Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome | Q78534522 | ||
| Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease | Q79909161 | ||
| Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? | Q81308307 | ||
| CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation | Q81523802 | ||
| Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival | Q83149379 | ||
| Non-Hodgkin's lymphomas, version 2.2014 | Q88071273 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2665-2673 | |
| P577 | publication date | 2015-05-18 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder | |
| P478 | volume | 15 |
| Q95841150 | Biological Difference Between Epstein-Barr Virus Positive and Negative Post-transplant Lymphoproliferative Disorders and Their Clinical Impact |
| Q38877813 | Both high and low levels of cellular Epstein-Barr virus DNA in blood identify failure after hematologic stem cell transplantation in conjunction with acute GVHD and type of conditioning |
| Q93139625 | Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders |
| Q47572480 | Comprehensive review of post-organ transplant hematologic cancers |
| Q91676550 | Cutaneous plasmacytoma-like posttransplant lymphoproliferative disorder after renal transplantation with response to imiquimod 5% cream and reduced immunosuppression |
| Q33594139 | EBV-Negative Monomorphic B-Cell Posttransplant Lymphoproliferative Disorder with Marked Morphologic Pleomorphism and Pathogenic Mutations in ASXL1, BCOR, CDKN2A, NF1, and TP53 |
| Q40094003 | EBV-Positive and EBV-Negative Posttransplant Diffuse Large B Cell Lymphomas Have Distinct Genomic and Transcriptomic Features |
| Q64120868 | Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders |
| Q89551910 | Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorders after Hematopoietic Stem Cell Transplantation: Pathogenesis, Risk Factors and Clinical Outcomes |
| Q92023502 | Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities |
| Q51734713 | Impact of the posttransplant lymphoproliferative disorder subtype on survival. |
| Q30238810 | Infection in Organ Transplantation |
| Q26776151 | Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders |
| Q94476138 | Malignancy after lung transplantation |
| Q88802166 | Management of Non-Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder |
| Q40238236 | Mutational landscape of B-cell post-transplant lymphoproliferative disorders |
| Q91902643 | Post-Transplant Lymphoproliferative Disorder in a Kidney Transplant Recipient |
| Q42368054 | Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients |
| Q51733100 | Post-transplant lymphoproliferative disorder of the bladder in a lung transplant recipient. |
| Q47611981 | Post-transplant lymphoproliferative disorder: a heterogeneous conundrum |
| Q89217688 | Post-transplant lymphoproliferative disorders |
| Q90748114 | Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches |
| Q47799831 | Posttransplant Lymphoproliferative Disorder After Clinical Islet Transplantation: Report of the First Two Cases |
| Q38680172 | Posttransplant Lymphoproliferative Disorder: Otolaryngological Manifestations and Management |
| Q47148062 | Posttransplant lymphoproliferative disorders in kidney transplant recipients: a retrospective cohort analysis over two decades in Hong Kong. |
| Q53183825 | Pre-transplant diastolic but not systolic dysfunction has a negative prognostic impact after allogeneic stem cell transplantation. |
| Q28075701 | Recent insights in the pathogenesis of post-transplantation lymphoproliferative disorders |
| Q50909795 | Shaping the Molecular Landscape of Posttransplantation Lymphoproliferative Disorders. |
| Q58083290 | Very late onset post-transplant diffuse large B cell lymphoma in a liver transplant recipient with hepatitis B: A case report |
Search more.